hyperglycemia is not always evident through traditional mean glucose tests such as HbA1c. GlycoMark offers insight into hyperglycemia that other tests can’t.
(PRWEB) August 04, 2016
GlycoMark, Inc. announced it has partnered with Diazyme Laboratories to offer the first diabetes panel to test three different measures of glycemic control on one specimen. The panel includes assays that measure both intermediate-term and long-term glucose averages (Diazyme’s Glycated Serum Protein/GSP and Enzymatic HbA1c) along with GlycoMark—a test specifically related to hyperglycemia over a one- to two-week period. The announcement was made at the 68th AACC Annual Scientific Meeting and Clinical Lab Expo.
The GlycoMark test measures the 1,5-anhydroglucitol molecule in the blood, providing a clinically proven one- to two-week measure of glycemic excursions often related to post prandial sugar spikes. GlycoMark has been a standard part of diabetes testing in Japan for over 20 years and has been the subject of more than 40 clinical trials around the world. Its partnership with Diazyme marks the first full scale entry into the U.S. market.
“Recent studies clearly link hyperglycemia to increased incidence of cardiovascular disease, neuropathy, tissue damage and death, yet hyperglycemia is not always evident through traditional mean glucose tests such as HbA1c,” said President of GlycoMark, Larry Thomas. “GlycoMark offers insight into hyperglycemia that other tests can’t.”
Long known for its innovation in clinical diagnostics, Diazyme draws from three separate biomarkers for improved diabetes monitoring and diagnosis. Its direct Enzymatic HbA1c provides a long-term average glucose resistant to interference from hemoglobin variants HbS, HbC, HbE and from post transcript modifications while its Glycated Serum Protein/GSP (Glycated Albumin) is a two- to three-week indicator of average blood glucose.
“By combining their assays with GlycoMark, Diazyme continues its tradition of innovation, offering physicians a more complete picture of glycemic control than ever before,” Thomas said.
AACC is made up of approximately 8,000 members across 110 countries, working in all areas of lab medicine—clinical and research laboratories, diagnostic companies, government agencies, original equipment manufacturers, and more. It is the nation’s largest organization representing the public policy interests of clinical laboratories.
About Diazyme Laboratories
Diazyme is an innovative clinical chemistry reagent manufacture focused on a wide range of biomarkers for clinical and research testing including cardiovascular risk assessment, diabetes, liver, electrolytes, kidney, coagulation and iron status. Diazyme Laboratories is a Division of General Atomics located in Poway, California and is a cGMP and ISO 13485 certified medical device manufacturer. Information regarding Diazyme's enzyme technology and related products can be found on its website at http://www.diazyme.com.
GlycoMark, Inc. is a joint venture of Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan). The GlycoMark test is an FDA-cleared for intermediate monitoring of glucose control in people with diabetes. The GlycoMark test is not intended to diagnose any specific diabetes state or disease. Physicians should use their clinical judgment when using the GlycoMark test. For more information, visit http://www.GlycoMark.com.